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A bs tr ac t
Background
Nesiritide is approved in the United States for early relief of dyspnea in patients with 
acute heart failure. Previous meta-analyses have raised questions regarding renal toxic-
ity and the mortality associated with this agent.
Methods
We randomly assigned 7141 patients who were hospitalized with acute heart failure to 
receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. 
Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on 
a 7-point Likert scale, and the composite end point of rehospitalization for heart fail-
ure or death within 30 days.
Results
Patients randomly assigned to nesiritide, as compared with those assigned to placebo, 
more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% 
vs. 42.1%, P = 0.03) and 24 hours (68.2% vs. 66.1%, P = 0.007), but the prespecified level 
for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. 
The rate of rehospitalization for heart failure or death from any cause within 30 days 
was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute differ-
ence, −0.7 percentage points; 95% confidence interval [CI], −2.1 to 0.7; P = 0.31). 
There were no significant differences in rates of death from any cause at 30 days 
(3.6% with nesiritide vs. 4.0% with placebo; absolute difference, −0.4 percentage 
points; 95% CI, −1.3 to 0.5) or rates of worsening renal function, defined by more 
than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; 
odds ratio, 1.09; 95% CI, 0.98 to 1.21; P = 0.11).
Conclusions
Nesiritide was not associated with an increase or a decrease in the rate of death and 
rehospitalization and had a small, nonsignificant effect on dyspnea when used in 
combination with other therapies. It was not associated with a worsening of renal 
function, but it was associated with an increase in rates of hypotension. On the basis 
of these results, nesiritide cannot be recommended for routine use in the broad 
population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov 
number, NCT00475852.)
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A cute decompensated heart failure is a major health problem that is associated with several million hospitalizations world-
wide each year, poor short-term outcomes, and 
high costs.1-3 Despite the magnitude of the prob-
lem, rates of early death and rehospitalization have 
not improved over the past several decades.3
Nesiritide, a recombinant B-type natriuretic 
peptide (BNP) with vasodilatory properties,4-7 was 
approved in 2001 for use in patients with acute 
heart failure on the basis of studies showing a 
reduction in pulmonary-capillary wedge pressure 
and improvement in dyspnea at 3 hours.5,6,8 How-
ever, subsequent pooled analyses of data from 
small, randomized trials suggested that nesiritide, 
as compared with placebo, was associated with 
a rate of worsening renal function that was in-
creased by a factor of 1.5 and a rate of early death 
that was increased by a factor of 1.8, although the 
confidence intervals associated with these esti-
mates were wide.9,10
An independent panel convened to evaluate this 
issue recommended that a large clinical trial be 
conducted to answer the question of whether ne-
siritide is effective and safe.11 Accordingly, the 
Acute Study of Clinical Effectiveness of Nesiritide 
in Decompensated Heart Failure (ASCEND-HF) 
trial was designed to evaluate the effect of nesiri-
tide, in addition to standard care, on rates of self-
reported dyspnea at 6 and 24 hours, rehospitaliza-
tion for heart failure or death from any cause at 
30 days, and renal dysfunction.
Me thods
Study Design and Oversight
The ASCEND-HF was a randomized, double-blind, 
placebo-controlled trial of nesiritide in addition to 
standard care. The study design has been published 
elsewhere,12 and the study protocol is available with 
the full text of this article at NEJM.org. The trial 
was conducted from May 2007 through August 
2010 at 398 centers throughout the world. The 
study was approved by each participating center’s 
ethics committee or institutional review board, and 
all participants provided written informed consent. 
Research sites in North America were managed by 
a consortium of academic research organizations 
that included the Canadian VIGOUR Centre, the 
Cleveland Clinic’s C5 Research Group, the Duke 
Clinical Research Institute, the Henry Ford Coor-
dinating Center, and the Jefferson Coordinating 
Center for Clinical Research.
The Duke Clinical Research Institute performed 
study-data processing and statistical analyses, and 
the Duke Clinical Research Institute, a network of 
academic research organizations, and Johnson & 
Johnson Pharmaceutical Research and Develop-
ment managed the study at the participating sites. 
The executive committee was responsible for the 
trial design, and the steering committee super-
vised patient recruitment and clinical management 
of the trial. Before the database was locked, only 
the drug-distribution group and the data and 
safety monitoring board maintained the code for 
group assignments. The manuscript was initially 
drafted by the academic authors, and it was written 
independently of the sponsor by the executive and 
steering committees. The sponsor was allowed to 
comment on the manuscript before submission, 
but all final decisions were made by the executive 
committee. An independent data and safety mon-
itoring board met after every 1000 patients had 
been recruited, and statistical analyses were con-
ducted by Frontier Science and Technology Re-
search Foundation independently of the sponsor.
After the database was locked, the sponsor and 
executive committee were made aware of potential 
quality issues at one site that had randomly as-
signed 121 patients to a study group. The site used 
duplicate copies of electrocardiographic tracings 
as data for more than one subject or subject visit 
date. Additional statistical analyses performed to 
determine whether other data were potentially af-
fected did not identify any other data abnormali-
ties. Since this information was obtained after the 
database was locked and the overall study results 
were unblinded, and sensitivity analyses censoring 
data from this site showed no material change in 
the efficacy or safety analyses or conclusions, the 
decision was made not to alter the data sets in 
the primary analysis. The first author vouches for 
the completeness and accuracy of the data and the 
analyses as well as the fidelity of the study to the 
protocol.
Study Patients
Patients were eligible to participate in the study if 
they were hospitalized for heart failure occurring 
within 24 hours before they received their first in-
travenous treatment for heart failure or if they had 
received a diagnosis of acute decompensated heart 
failure less than 48 hours after hospitalization 
for another cause and underwent randomization 
within 24 hours after intravenous treatment for 
heart failure. Additional criteria at the time of 
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randomization included the following: dyspnea at 
rest or with minimal activity, one or more accom-
panying signs (respiratory rate ≥20 breaths per 
minute or pulmonary congestion or edema with 
rales one third of the way or more up the lung 
fields), and one or more objective measures of 
heart failure (evidence of congestion or edema on 
chest radiography, a BNP level ≥400 pg per mil-
liliter or an N-terminal pro-BNP level ≥1000 pg 
per milliliter, pulmonary-capillary wedge pressure 
>20 mm Hg, or left ventricular ejection fraction 
<40% in the previous 12 months).12
Key exclusion criteria were a high risk of hy-
potension (systolic pressure <100 mm Hg or 
110 mm Hg with the use of intravenous nitro-
glycerin), other contraindications for vasodilators, 
treatment with dobutamine (at a dose ≥5 μg per 
kilogram of body weight per minute), treatment 
with milrinone or levosimendan within the previ-
ous 30 days, persistent uncontrolled hypertension, 
acute coronary syndrome, normal level of BNP or 
N-terminal pro-BNP, severe pulmonary disease, 
end-stage renal disease during receipt of renal-
replacement therapy, and clinically significant ane-
mia. Complete eligibility criteria are described 
elsewhere12 and in the study protocol.
Study-Drug Administration
Eligible patients were randomly assigned in a 1:1 
ratio to receive nesiritide or placebo. All partici-
pants received standard therapies, including di-
uretics, morphine, and other vasoactive medica-
tions, as determined by the investigator with the 
guidance of a standard-of-care manual.13 After a 
recommended but optional intravenous bolus of 
nesiritide, at a dose of 2 μg per kilogram (admin-
istered at the discretion of the investigator), ne-
siritide was administered as a continuous infu-
sion of 0.010 μg per kilogram per minute for 
24 hours or more for up to 7 days.
End Points
The study had two coprimary end points: the 
change in self-reported dyspnea 6 and 24 hours 
after study-drug initiation and the composite end 
point of rehospitalization for heart failure and 
death from any cause during the period from ran-
domization to day 30. Dyspnea was measured 
with the use of a self-reported 7-point categorical 
Likert scale, ranging from “markedly better” to 
“markedly worse,” as compared with the degree of 
dyspnea present at the start time of study-drug ad-
ministration. Rehospitalization and fatal events 
within 30 days after randomization were reviewed 
and categorized by an independent, blinded clini-
cal-events committee at the University of Glasgow. 
The following criteria were required for hospital-
ization events to be classified as due to heart fail-
ure: typical clinical manifestations of worsening 
heart failure and the addition of (or increase in) 
treatment specifically for worsening heart failure 
with an intravenous pharmacologic agent, or me-
chanical or surgical intervention or ultrafiltration, 
hemofiltration, or dialysis specifically for man-
agement of persistent or worsening heart failure. 
Hospitalized patients who remained in the hospi-
tal at 30 days because of heart failure were count-
ed as being rehospitalized for heart failure in the 
analysis of the coprimary end point.
Secondary end points included self-reported 
overall well-being, measured 6 and 24 hours after 
study-drug initiation with the use of the 7-point 
Likert scale, the composite end point of persistent 
or worsening heart failure and death from any 
cause during the period from randomization 
through hospital discharge (index hospitalization), 
the number of days alive and out of the hospital 
through day 30, and the composite end point of 
death from cardiovascular causes and rehospital-
ization due to cardiovascular causes from ran-
domization through day 30.
Safety end points included death from any 
cause during the period from randomization 
through day 30; death from cardiovascular causes; 
sudden death from cardiac causes through day 30; 
need for renal replacement therapy (defined by 
>25% decrease from the baseline estimated glo-
merular filtration rate, calculated with the use of 
the simplified Modification of Diet in Renal Dis-
ease equation) at any time from study-drug ini-
tiation through day 30; and the occurrence of 
investigator-reported hypotension relative to the 
participant’s baseline blood pressure through hos-
pital discharge or 10 days after study-drug initia-
tion, whichever occurred first.
Statistical Analysis
Calculation of the sample size was based on the 
composite end point of rehospitalization for heart 
failure or death from any cause through day 30. The 
planned enrollment of 7000 patients was estimat-
ed to provide 89% power, with the use of the chi-
square test and a two-sided alpha level of 0.045, to 
detect a difference between groups, assuming an 
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event rate of 11.4% in the nesiritide group and an 
event rate of 14.0% in the placebo group (relative 
risk reduction, 18.6%). For the dyspnea end point, 
this sample size was estimated to provide 99% 
power, with the use of the Wilcoxon rank-sum test 
and a two-sided alpha level of 0.0025, to detect an 
effect size of 0.543 between the nesiritide and pla-
cebo groups (translating to a 54.3% probability that 
a patient receiving nesiritide would report a better 
outcome than a patient receiving placebo).
The differences between study drugs with re-
spect to the binary composite end point and the 
renal end points were estimated with the use of the 
Cochran–Mantel–Haenszel test, stratified accord-
ing to region. Hypotension was compared between 
treatment groups with the use of a chi-square test. 
Ordinal variables (scores on the Likert scale) were 
compared with the use of the van Elteren test,14 
with adjustment for region. The numbers of days 
that patients were alive and out of the hospital were 
assessed with the use of analysis of variance, with 
adjustment for region.
Differing views on the part of regulators in the 
United States and Europe regarding the primacy 
of end points led to the creation of two analysis 
plans. The primary analysis plan tested the copri-
mary end points with the use of a Bonferroni ap-
proach. The composite of rehospitalization for 
heart failure and death from any cause at day 30 
was tested at the 0.045 significance level, and the 
assessments of dyspnea at 6 and 24 hours were 
tested at the 0.005 level with the use of the Hoch-
berg method. The dyspnea end point was consid-
ered significant if the P values were ≤0.005 at both 
6 and 24 hours, or if either of the two P values was 
≤0.0025. If the coprimary composite efficacy end 
point was significant at the specified level of 0.045, 
the analysis of the secondary end points was to be 
performed sequentially at an alpha level of 0.045 
with the use of closed-testing principles (or 0.05 as 
specified by the European Medicines Agency).
The European Medicines Agency considered 
the dyspnea end points to be primary efficacy end 
points and rehospitalization for heart failure (com-
bined with mortality) to be a secondary end point, 
so that Bonferroni correction was not part of the 
analysis plan required by that agency. Thus, for the 
regulatory purposes of the European Medicines 
Agency, the primary end points were dyspnea 
alone at 6 and 24 hours, and these end points 
were tested at an alpha level of 0.05 with the use 
of the Hochberg method, with statistical signifi-
cance indicated by a P value of 0.05 or less for both 
the 6- and 24-hour assessments or by a P value of 
0.025 or less for one of the assessments.
The following prespecified subgroup analyses 
were performed to evaluate the homogeneity of 
treatment effects on primary and secondary end 
points: geographic region; use or nonuse of a 
study-drug bolus; use or nonuse of an inotropic 
agent, intravenous vasodilator, or intravenous ni-
troglycerin at randomization; use or nonuse of a 
diuretic from the onset of the qualifying episode 
of heart failure through randomization; sex; age; 
race or ethnic group; baseline renal function, ejec-
tion fraction, and systolic blood pressure; and 
presence or absence of a history of coronary ar-
tery disease or diabetes mellitus.
Primary efficacy analyses and safety analyses 
were performed for the modified intention-to-treat 
population, defined as all randomly assigned par-
ticipants who received any amount of study medi-
cation. Efficacy analyses were conducted according 
to randomized treatment assignment; safety anal-
yses were conducted according to actual treatment 
received. All statistical analyses were performed 
with the use of SAS software, version 9.2 (SAS In-
stitute).
R esult s
Patient Population
From May 2007 through August 2010, a total of 
7141 patients underwent randomization at 398 sites 
in North America, Europe, Latin America, and the 
Asia–Pacific region. Of these participants, 7007 
(98%) received a study drug (3496 patients assigned 
to nesiritide and 3511 assigned to placebo) and 
were included in the modified intention-to-treat 
analysis (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). The study groups were well 
balanced and similar in all respects (Table 1) and 
similar to the intention-to-treat group.
Coprimary End Points
The distribution of patient-reported assessments of 
dyspnea at 6 and 24 hours is shown in Figure 1A. 
Although a small increase in the number of pa-
tients reporting improvement in dyspnea was ob-
served at both the 6- and 24-hour time points, this 
finding did not meet the prespecified criteria for 
significance.
Rehospitalization for heart failure or death 
from any cause at 30 days (Fig. 1B) occurred in 
The New England Journal of Medicine 
Downloaded from nejm.org by MARCO METRA on July 10, 2011. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;1 nejm.org july 7, 201136
321 patients in the nesiritide group (9.4%) as 
compared with 345 patients in the placebo group 
(10.1%) (absolute difference, −0.7 percentage 
points; 95% confidence interval [CI], −2.1 to 0.7; 
P = 0.31). Individual components of the primary 
end point are shown in Table 2. The time-to-event 
analysis showed similar results for the composite 
end point, with a hazard ratio for death from any 
Table 1. Characteristics of the Modified Intention-to-Treat Population.*
Characteristic
Nesiritide
(N = 3496)
Placebo
(N = 3511)
Age — yr
Median 67 67
Interquartile range 56–76 56–76
Sex — no./total no. (%)
Female 1167/3496 (33.4) 1224/3511 (34.9)
Male 2329/3496 (66.6) 2287/3511 (65.1)
Race — no./total no. (%)†
White 1964/3496 (56.2) 1952/3511 (55.6)
Black  513/3496 (14.7)  527/3511 (15.0)
Asian  873/3496 (25.0)  874/3511 (24.9)
Other 145/3496 (4.1) 158/3511 (4.5)
Systolic pressure — mm Hg
Median 123 124
Interquartile range 110–140 110–140
Heart rate at rest — beats/min
Median 82 82
Interquartile range 72–95 72–95
BNP — pg/ml‡
Median 994 989
Interquartile range 544–1925 543–1782
N-terminal pro-BNP — pg/ml§
Median 4508 4461
Interquartile range 2076–9174 2123–9217
Creatinine — mg/dl
Median 1.2 1.2
Interquartile range 1.0–1.5 1.0–1.6
Serum sodium — mmol/liter
Median 139 139
Interquartile range 136–141 136–141
Left ventricular ejection fraction within previous 12 mo — no./total no. (%)¶
<40% 2127/2632 (80.8) 2106/2649 (79.5)
≥40%  505/2632 (19.2)  543/2649 (20.5)
Medical history — no./total no. ( %)
Heart failure 1 yr before admission 1339/3492 (38.3) 1386/3508 (39.5)
Ischemic heart disease 2081/3496 (59.5) 2133/3511 (60.8)
Hypertension 2510/3496 (71.8) 2548/3511 (72.6)
Atrial fibrillation or flutter 1306/3496 (37.4) 1322/3511 (37.7)
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cause or rehospitalization for heart failure of 0.93 
(95% CI, 0.80 to 1.08) (Fig. S2 in the Supplemen-
tary Appendix).
Secondary End Points
Self-reported overall well-being at 6 and 24 hours 
did not differ significantly between the groups 
(Fig. S3 in the Supplementary Appendix). In addi-
tion, no significant differences between the groups 
were seen with respect to the secondary end points 
of rehospitalization for cardiovascular causes or 
death from cardiovascular causes, or total days 
alive and out of the hospital at 30 days. The end 
point of persistent or worsening heart failure 
or death from any cause from randomization 
through hospital discharge (index hospitalization) 
was also similar between the nesiritide and place-
bo groups (4.2% and 4.8%, respectively; absolute 
difference, −0.6 percentage points; 95% CI, −1.5 to 
0.5) (Table 2).
Safety End Points
There was no significant difference between the 
groups with respect to the rate of death from any 
cause at 30 days (Table 2). A total of 126 partici-
pants who received nesiritide (3.6%) and 141 par-
ticipants who received placebo (4.0%) died within 
30 days after randomization (absolute difference, 
−0.4 percentage points; 95% CI, −1.3 to 0.5). 
There was no significant difference between the 
Table 1. (Continued.)
Characteristic
Nesiritide
(N = 3496)
Placebo
(N = 3511)
Medical therapy before randomization — no./total no. (%)
ACE inhibitor or ARB 2088/3496 (59.7) 2168/3510 (61.8)
Beta-blocker 2005/3496 (57.4) 2069/3510 (58.9)
Aldosterone blocker  960/3496 (27.5)  990/3511 (28.2)
Nitrate (oral or topical)  823/3496 (23.5)  829/3511 (23.6)
Digoxin or digitalis glycoside  933/3495 (26.7)  929/3511 (26.5)
Hydralazine 261/3496 (7.5) 257/3511 (7.3)
Loop diuretic 3316/3496 (94.9) 3347/3511 (95.3)
Inotropic agent 151/3495 (4.3) 156/3510 (4.4)
Vasodilator  549/3496 (15.7)  496/3510 (14.1)
Use of medication from randomization through 24 hr — no./total no. (%)
Loop diuretic 3149/3496 (90.1) 3225/3511 (91.9)
Inotropic agent 228/3495 (6.5) 231/3508 (6.6)
Vasodilator  544/3495 (15.6)  511/3508 (14.6)
Time from hospitalization to randomization — hr
Median 15.3 15.7
Interquartile range 5.4–21.9 5.4–22.0
Time from randomization to study-drug administration — hr
Median 0.8 0.8
Interquartile range 0.5–1.4 0.5–1.4
Administration of study-drug bolus — no./total no. (%) 2172/3496 (62.1) 2160/3511 (61.5)
Duration of study-drug administration — hr
Median 41.0 43.0
Interquartile range 24.1–48.3 24.1–49.0
* Inotropic agents included dobutamine, dopamine, milrinone, levosimendan, vasopressin, enoximone, epinephrine, nor-
epinephrine, and phenylephrine. Vasodilators included intravenous nitroglycerin, nitroprusside, and open-label nesiritide. 
To convert the values for creatinine to micromoles per liter, multiply by 88.4. BNP denotes B-type natriuretic peptide.
† Race was self-reported.
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nesiritide group and the placebo group with re-
spect to the proportion of patients with renal im-
pairment at any time from randomization through 
day 30 (31.4% and 29.5%, respectively; odds ratio 
with nesiritide, 1.09; 95% CI, 0.98 to 1.21) (Table 
2), regardless of the degree of baseline renal in-
sufficiency.
The proportion of patients with an episode of 
hypotension was significantly greater in the ne-
siritide group than in the placebo group (26.6% vs. 
15.3%, P<0.001), with a median systolic pressure 
of 80 mm Hg (interquartile range, 70 to 87) during 
the episode among patients who received nesiri-
tide and 80 mm Hg (interquartile range, 70 to 85) 
among patients who received placebo. Both asymp-
tomatic hypotension and symptomatic hypoten-
sion occurred more often in patients who received 
nesiritide than in patients who received placebo 
(asymptomatic, 21.4% vs. 12.4%; symptomatic, 
7.2% vs. 4.0%; P<0.001 for both comparisons) 
(Table 2). No significant differences in serious ad-
verse events were observed (Table S1 in the Supple-
mentary Appendix)
Subgroup Analyses
The coprimary outcome of rehospitalization for 
heart failure or death from any cause within 30 
days was consistent across prespecified subgroups 
(Fig. 2). Likewise, the results of the subgroup anal-
ysis for the coprimary end point of self-reported 
dyspnea were consistent across prespecified groups 
(Fig. 3).
Discussion
In this trial, the use of nesiritide in patients with 
acute decompensated heart failure neither in-
creased nor decreased the incidence of death or 
rehospitalization for heart failure at 30 days. Self-
reported dyspnea at 6 and 24 hours was margin-
ally improved when nesiritide was added to con-
ventional therapy, but this finding did not meet 
prespecified criteria for statistical significance. 
Nesiritide thus cannot be recommended in the 
broad population of patients with acute decom-
pensated heart failure represented by the study 
population in this trial.
The effect of nesiritide on the dyspnea end point 
in this trial was consistent with the findings of the 
Vasodilation in the Management of Acute Conges-
tive Heart Failure (VMAC; ClinicalTrials.gov num-
ber, NCT00270374) trial that formed the basis for 
the Food and Drug Administration’s approval of 
nesiritide. The VMAC study included only 498 
patients, and the significant effect on dyspnea at 
3 hours was observed for nesiritide as compared 
with placebo, but this effect was similar to that 
of intravenous nitroglycerin, and no significant 
effect was detected at 24 hours.6 The VMAC pro-
tocol encouraged the withholding of additional 
therapy unless it was required because of worsen-
ing symptoms. Analyses in the current trial showed 
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Figure 1. Changes in Dyspnea at 6 and 24 Hours and the Primary Clinical 
End Points at 30 Days.
In Panel A, the number above the bar indicates the overall percentage of 
patients who reported being markedly or moderately better after receiving 
study treatment (i.e., those represented by the percentages above the 
dashed line).
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Table 2. Primary and Secondary Clinical End Points and Safety End Points through Day 30.*
End Point
Nesiritide
(N = 3496)
Placebo
(N = 3511)
Percentage-Point 
Difference or Odds 
Ratio (95% CI)† P Value
Primary clinical end points
Death from any cause or rehospitalization for heart failure — 
no./total no. (%)
321/3423 (9.4) 345/3413 (10.1) −0.7 (−2.1 to 0.7) 0.31
Death from any cause 126/3490 (3.6) 141/3499 (4.0) −0.4 (−1.3 to 0.5)
Rehospitalization for heart failure 204/3422 (6.0) 208/3411 (6.1) −0.1 (−1.2 to 1.0)
Secondary clinical end points
Persistent or worsening heart failure or death from any cause 
through hospital discharge — no./total no. (%)
147/3459 (4.2) 165/3462 (4.8) −0.6 (−1.5 to 0.5) 0.30
Days alive and out of hospital through day 30 20.9±6.9 20.7±7.1 0.2 (−0.13 to 0.53) 0.16
Rehospitalization or death from cardiovascular causes —  
no./total no. (%)
372/3423 (10.9) 402/3415 (11.8) −0.9 (−2.4 to 0.6) 0.24
Safety end points
Death from cardiovascular causes — no./total no. (%) 112/3498 (3.2) 124/3509 (3.5) −0.3 (−1.2 to 0.5) 0.44
Sudden death from cardiac causes — no./total no. (%) 19/3324 (0.6) 16/3327 (0.5) 0.1 (−0.3 to 0.4) 0.61
Hypotension — no./total no. (%) 930/3498 (26.6) 538/3509 (15.3) 11.3 (9.4 to 13.1) <0.001
Asymptomatic 748/3498 (21.4) 436/3509 (12.4) 9.0 (7.2 to 10.7) <0.001
Symptomatic 250/3496 (7.2) 141/3509 (4.0) 3.2 (2.1 to 4.2) <0.001
>25% decrease in estimated GFR from study-drug initiation — 
no./total no. (%)
1032/3289 (31.4) 968/3278 (29.5) 1.09 (0.98 to 1.21) 0.11
Baseline estimated GFR <60 ml/min/1.73 m2 484/1714 (28.2) 449/1717 (26.2) 1.11 (0.96 to 1.3) 0.16
Baseline estimated GFR ³≥60 ml/min/1.73 m2 548/1575 (34.8) 519/1561 (33.2) 1.07 (0.92 to 1.24) 0.38
* Plus–minus values are means ±SD. CI denotes confidence interval, and GFR glomerular filtration rate.
† Data shown are percentage-point differences, with the exception of data for >25% decrease in estimated GFR from study-drug initiation, for 
which the data shown are odds ratios.
a small effect of nesiritide on dyspnea in most of 
the participants who received other therapies 
before and during study-drug infusion; these find-
ings are consistent with the VMAC study results 
showing a smaller effect of nesiritide as compared 
with an active control of nitroglycerin, in con-
trast to nesiritide versus placebo.
In this era of comparative effectiveness assess-
ments, we know little about the comparative ef-
fectiveness of standard treatments for acute heart 
failure, including diuretics,15-19 morphine,20 ino-
tropic agents,21 oxygen,22 and vasodilators such as 
nitroglycerin.15
The development of nesiritide poses fundamen-
tal questions about the manner in which therapies 
are developed and assessed. Because nesiritide was 
not studied in a major outcome trial early in its life 
cycle, both patients and physicians lacked an ap-
propriate understanding of the proper role of the 
drug in practice. Our findings also underscore the 
fact that systematic overviews with small numbers 
of events can yield unreliable estimates of the bal-
ance of benefits and risks, and interpretation of 
the data is confounded by these imprecise esti-
mates. An updated systematic overview of 30-day 
mortality data in trials involving patients with 
acute decompensated heart failure that compared 
nesiritide with placebo or other control agents 
showed no adverse effect of nesiritide on survival9 
(Fig. S4 in the Supplementary Appendix).
This international trial was subject to differing 
regulatory views regarding the most appropriate 
analysis plan. According to the primary statistical 
analysis plan, the effect of nesiritide on dyspnea, 
although numerically superior, was not significant, 
whereas analyses required by the European Med-
icines Agency resulted in a significant result — a 
divergence that shows the need for better harmo-
nization of regulatory views.23 Regardless of which 
statistical and regulatory plan is considered, the 
supporting analyses point to a conclusion that is 
consistent with previous findings.
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Figure 2. Subgroup Analyses of Rehospitalization for Heart Failure or Death from Any Cause, from Randomization 
through Day 30.
Data on race, systolic pressure, ejection fraction (EF), estimated glomerular filtration rate (GFR), and coronary artery 
disease were not available for some patients.
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Figure 3. Subgroup Analysis of Dyspnea at 6 and 24 Hours.
Data on race, systolic pressure, ejection fraction (EF), estimated glomerular filtration rate (GFR), and coronary artery disease were not 
available for some patients.
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Several limitations of this trial should be not-
ed. First, the trial primarily addressed safety con-
cerns; thus, the design was intentionally permis-
sive so that the study population would include a 
broad range of patients with acute decompensat-
ed heart failure. Second, the evaluation of dyspnea 
remains rudimentary, despite the number of stud-
ies that have used the 7-point Likert scale, and the 
minimal clinically important difference between 
treated and untreated groups remains unclear.24 
Third, the clinical-event rate was lower than ex-
pected, and in future trials, samples approach-
ing 10,000 subjects would be required to provide 
greater certainty regarding clinically relevant end 
points.
In summary, in this study, nesiritide neither 
increased nor decreased the rate of death and re-
hospitalization. The observed effect of nesiritide 
on dyspnea in this trial was small (and not sig-
nificant) with the coadministration of other ther-
apies that relieve congestion. Nesiritide was not 
associated with worsened renal function, but it was 
associated with an increase in the rate of hypo-
tension. In hindsight, nesiritide was approved and 
swiftly adopted in the United States because of its 
perceived large benefit in relieving dyspnea and 
congestion, and then its use markedly decreased 
because of published meta-analyses reporting a 
detrimental effect on survival and renal function.25 
Our study showed that neither belief was accurate. 
The results of this trial highlight the urgent need 
for rigorously designed trials with adequate pow-
er to provide reliable estimates that can replace 
incomplete or inadequate evidence as a basis for 
therapeutic decisions.
Presented in part at the 2010 scientific sessions of the Ameri-
can Heart Association, Chicago, November 14–17, 2010.
Supported by Scios.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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